Oremus M

References (4)

Title : A pharmacoeconomic evaluation of cholinesterase inhibitors and memantine for the treatment of Alzheimer's disease - Ebrahem_2018_Expert.Opin.Pharmacother_19_1245
Author(s) : Ebrahem AS , Oremus M
Ref : Expert Opin Pharmacother , 19 :1245 , 2018
Abstract :
PubMedSearch : Ebrahem_2018_Expert.Opin.Pharmacother_19_1245
PubMedID: 29999427

Title : Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline - Raina_2008_Ann.Intern.Med_148_379
Author(s) : Raina P , Santaguida P , Ismaila A , Patterson C , Cowan D , Levine M , Booker L , Oremus M
Ref : Ann Intern Med , 148 :379 , 2008
Abstract :
PubMedSearch : Raina_2008_Ann.Intern.Med_148_379
PubMedID: 18316756

Title : Caregiver acceptance of adverse effects and use of cholinesterase inhibitors in Alzheimer's disease - Oremus_2007_Can.J.Aging_26_205
Author(s) : Oremus M , Wolfson C , Vandal AC , Bergman H , Xie Q
Ref : Can J Aging , 26 :205 , 2007
Abstract :
PubMedSearch : Oremus_2007_Can.J.Aging_26_205
PubMedID: 18238727

Title : Physicians' efficacy requirements for prescribing medications to persons with Alzheimer's disease - Oremus_2007_Can.J.Aging_26_139
Author(s) : Oremus M , Wolfson C , Bergman H , Vandal AC
Ref : Can J Aging , 26 :139 , 2007
Abstract :
PubMedSearch : Oremus_2007_Can.J.Aging_26_139
PubMedID: 17613445